Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $3.0M | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $23.0M | $30.6M | $21.0M | $18.9M | $14.1M | $14.5M | $15.2M |
| Operating income | −$28.6M | −$37.5M | −$29.8M | −$35.9M | −$36.2M | −$24.2M | −$23.1M |
| EBITDA | −$28.2M | −$37.2M | −$29.8M | −$35.9M | −$29.3M | $58.0K | $46.0K |
| Net income | −$28.4M | −$36.6M | −$27.5M | −$35.8M | −$35.6M | −$13.7M | −$29.6M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -2.36 | -35.47 | -57.10 | -22.34 | -23.24 | -1.22 | -1.97 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds GRAY.
No tracked institution reports a position in GRAY as of their last filing.
No one on the platform has traded GRAY yet.
| $125M |
| — |
| NGMNGM Biopharmaceuticals, Inc. | $1.54 | -1.28% | $129M | — |
| PRTKParatek Pharmaceuticals, Inc. | $2.23 | +1.83% | $128M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.